Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,188 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes.
Takagi T, Kondo T, Tachibana H, Iizuka J, Omae K, Kobayashi H, Yoshida K, Hashimoto Y, Tanabe K. Takagi T, et al. Among authors: tachibana h. Int Urol Nephrol. 2016 Oct;48(10):1585-91. doi: 10.1007/s11255-016-1323-y. Epub 2016 Jun 4. Int Urol Nephrol. 2016. PMID: 27262849
Comparison of Surgical Outcomes Between Resection and Enucleation in Robot-Assisted Laparoscopic Partial Nephrectomy for Renal Tumors According to the Surface-Intermediate-Base Margin Score: A Propensity Score-Matched Study.
Takagi T, Kondo T, Tachibana H, Iizuka J, Omae K, Yoshida K, Kobayashi H, Okumi M, Ishida H, Tanabe K. Takagi T, et al. Among authors: tachibana h. J Endourol. 2017 Aug;31(8):756-761. doi: 10.1089/end.2017.0260. Epub 2017 Jun 20. J Endourol. 2017. PMID: 28537438
Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
Ishihara H, Takagi T, Kondo T, Tachibana H, Yoshida K, Omae K, Iizuka J, Kobayashi H, Tanabe K. Ishihara H, et al. Among authors: tachibana h. Int J Clin Oncol. 2018 Jun;23(3):559-567. doi: 10.1007/s10147-018-1241-3. Epub 2018 Jan 11. Int J Clin Oncol. 2018. PMID: 29327159 Clinical Trial.
1,188 results